Action brought on 23 January 2015 — Novartis v OHIM — Mabxience (HERTIXAN)

(Case T-41/15)

(2015/C 107/42)

Language in which the application was lodged: English

Parties

Applicant: Novartis AG (Basel, Switzerland) (represented by: M. Douglas, lawyer)

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

Other party to the proceedings before the Board of Appeal: Mabxience SA (Montevideo, Uruguay)

Details of the proceedings before OHIM

Applicant: Other party to the proceedings before the Board of Appeal

Trade mark at issue: Community word mark ‘HERTIXAN’ — Application for registration No 10 660 835

Procedure before OHIM: Opposition proceedings

Contested decision: Decision of the First Board of Appeal of OHIM of 31 October 2014 in Case R 2550/2013-1

Form of order sought

The applicant claims that the Court should:

—	annul the contested decision;

—	order OHIM to pay the costs.

Plea(s) in law

—	Infringement of Article 8(1)(b) of Regulation No 207/2009;

—	Infringement of Article 42(2) and (3) of Regulation No 207/2009;

—	Infringement of Article 75 of Regulation No 207/2009.